Research to be presented in a joint poster session with
Labcorp at the 2024 San Antonio Breast Cancer Symposium
BOSTON and BURLINGTON, N.C., Nov. 26,
2024 /PRNewswire/ -- Outcomes4Me Inc., the developer
of the first and only end-to-end, actionable cancer platform,
announced today it has been selected to present the results of a
biomarker awareness study, conducted with Labcorp, a global leader
of innovative and comprehensive laboratory services, at the
prestigious 2024 San Antonio Breast Cancer Symposium (SABCS) on
December 13, 2024. SABCS is the
preeminent conference for sharing cutting-edge breast cancer
research with healthcare professionals, researchers, and patient
advocates worldwide.
"Following the results of the DESTINY-BREAST04 trial at the
American Society of Clinical Oncology meeting in 2022, HER2-low
emerged as an important biomarker within metastatic breast cancer
(mBC)," said Maya R. Said, Sc.D.,
Founder and CEO of Outcomes4Me. "We knew that many patients living
with mBC would benefit from understanding their HER2-low status. We
recognize the need to translate the latest clinical research into
clinical practice in a timely manner, however, studies have
demonstrated that there can be significant delays in disseminating
new research findings for broad clinical use in the community. A
key component in efficient translation of research into clinical
practice is communication with all stakeholders, including
patients."
"Our direct-to-patient approach gives patients the tools to have
the right conversation with their doctor, in an effort to
accelerate guideline-concordant care," Said continued. "We
approached Labcorp to collaborate on this patient awareness program
because we knew that we could help save lives by doing so."
Utilizing Outcomes4Me's direct-to-patient digital platform,
Outcomes4Me and Labcorp developed an educational campaign comprised
of a doctor-patient discussion guide, a live and archived webinar,
and patient-friendly information and content about HER2-testing and
HER2-low breast cancer.
"Labcorp is committed to ensuring that patients have access to
the right tests and treatments, and self-advocacy is a key
component of that," said Dr. Rebecca
Previs, Director of Medical Affairs at Labcorp Oncology.
"Our collaboration with Outcomes4Me was a great opportunity to
connect directly with patients to empower them with the information
they needed to proactively broach HER2 testing with their
providers."
A pre-campaign survey found that 41.9% of patients with a known
HER2 status were not at all aware or not very aware of the HER2-low
classification. More than half of patients (51.3%) who were
classified as HER2-negative following their most recent testing did
not recall their oncologist discussing HER2-low as a possibility
with them. Recent advances in testing and scoring breast cancer
have indicated that many patients previously identified as
HER2-negative may meet criteria for HER2-low status. After engaging
with education in the Outcomes4Me app, 60.9% of patients with
unknown HER2 status felt very or somewhat likely to talk to their
oncologist about testing for HER2-low.
The results of this study affirm that patient-centric biomarker
education about HER2-low both increases biomarker awareness and
drives the willingness of patients to initiate a conversation
around biomarker testing and HER2 status with their provider. The
study highlights the benefits of collaboration between diagnostic
companies and digital health platforms that directly engage
patients, ultimately improving testing rates and patient outcomes.
The complete poster will be on display on Friday, December 13, 2024 from 12:00-2:00pm. Outcomes4Me is also exhibiting at
SABCS and will be located at Booth #1250.
About Outcomes4Me
Named a 2024 Fast Company World
Changing Idea, Outcomes4Me is the first and only end-to-end,
AI-driven patient empowerment platform that helps cancer patients
take a proactive approach to their care from diagnosis throughout
every stage of life and care. Through its patented technology, the
company is on a mission to democratize healthcare by providing
personalized, real-time, evidence-based information and resources
to cancer patients to address their clinical and emotional needs,
ensuring they can effectively navigate through their disease and
improve their outcomes. In doing so, Outcomes4Me is working to
promote health equity by generating deeper insights that improve
care, and accelerating research and access to innovation. Based in
Boston, Massachusetts, Outcomes4Me
is a woman-led company of seasoned healthcare, oncology,
pharmaceutical, consumer and technology veterans. For more
information, visit www.outcomes4me.com.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and
comprehensive laboratory services that helps doctors, hospitals,
pharmaceutical companies, researchers and patients make clear and
confident decisions. We provide insights and advance science to
improve health and improve lives through our unparalleled
diagnostics and drug development laboratory capabilities. The
company's more than 67,000 employees serve clients in approximately
100 countries, provided support for 84% of the new drugs and
therapeutic products approved in 2023 by the FDA, and performed
more than 600 million tests for patients around the world. Learn
more about us at www.labcorp.com.
View original
content:https://www.prnewswire.co.uk/news-releases/outcomes4me-and-labcorp-study-reveals-digital-education-can-increase-her2-low-awareness-for-metastatic-breast-cancer-patients-302316527.html